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Apixaban (factor Xa inhibitor) is a novel anticoagulant and may be beneficial during atrial 
fibrillation (AF) ablation for prevention of thromboembolic events. However, the adverse 
effects of periprocedural apixaban therapy have not been thoroughly evaluated.
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A meta-analysis was performed to evaluate the safety of apixaban for anticoagulation 
in AF ablation. We searched the online databases till September 2015 for studies 
comparing Apixaban with Vitamin K antagonists in atrial fibrillation patients 
undergoing catheter ablation. Primary outcome of our study was composite of 
thromboembolic event and bleeding (includes major and minor bleeding). 
A total of 1,057 atrial fibrillation patients in 3 studies undergoing catheter ablation 
were included in this analysis. Zero thromboembolic events were reported in the 
apixaban group and 1 in the VKA group with no statistical difference (95% CI 0.03-
18.49). No major differences were observed for the primary outcome (OR 0.92; 
95% CI 0.54-1.55), risk of overall bleeding (OR 0.94, 95% CI 0.55- 1.58), major 
bleeding (OR1.37; 95% CI 0.33-5.67), minor bleeding (OR 0.89; 95% CI 0.50-1.55), 
pericardial effusion (OR 0.50; 95% CI 0.18-1.38) and groin hematoma (OR 1.36; 
95% CI 0.70-2.65). 
Uninterrupted apixaban administration in patients undergoing AF catheter 
ablation was non-inferior to VKA without increasing the risk of major and 
minor bleeding. 
Figure 1: Forest plot of primary outcome, thromboembolic events, overall bleeding events, 
groin hematoma, pericardial effusion in patients undergoing ablation of atrial fibrillation with 
uninterrupted apixaban compared to uninterrupted vitamin K antagonist.
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Heterogeneity. Tau2 = 0.00: Chi2 = 1.26, df = 2 (P = 0.53); I2 = 0%





Test for subgroup differences: Chi2 = 2.99, df = 6 (P = 0.81), I2 = 0%
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